Results 151 to 160 of about 4,142 (167)

Guselkumab, an Anti-Interleukin-23 Monoclonal Antibody, for the Treatment of Moderate to Severe Plaque-Type Psoriasis in Japanese Patients: Efficacy and Safety Results From a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study

Journal of Dermatology, 2018
Hiroshi Kubo, Mamitaro Ohtsuki, Hitomi Morishima   +2 more
exaly  

Real-Life Experience of Guselkumab in Patients With Psoriasis

Dermatologic Therapy, 2020
Lev Pavlovsky, Emmilia Hodak, Igor Snast
exaly  

Apremilast/guselkumab

Reactions Weekly, 2022
openaire   +1 more source

Brodalumab/guselkumab

Reactions Weekly, 2021
openaire   +1 more source

Long-Term Single Center Experience in Treating Plaque Psoriasis With Guselkumab

Journal of Cutaneous Medicine and Surgery, 2020
Melinda Gooderham, Khalad Maliyar, Ashley O'Toole   +2 more
exaly  

Belimumab/guselkumab

Reactions Weekly, 2020
openaire   +1 more source

Evaluating Guselkumab: An Anti-IL-23 Antibody for the Treatment of Plaque Psoriasis

Drug Design, Development and Therapy, 2019
Tina Bhutani, Mary P Smith, Karen Ly
exaly  

Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis (QUASAR): Phase 3 Double-Blind, Randomised, Placebo-Controlled Induction and Maintenance Studies

Lancet, The
Yinglei Miao, Yassir Rayyan, Taro Osada
exaly  

Guselkumab (Tremfya) for Psoriasis

JAMA, 2017
openaire   +2 more sources

A Phase 2 Trial of Guselkumab Versus Adalimumab for Plaque Psoriasis

New England Journal of Medicine, 2015
Kristian Reich, Robert Bissonnette, Bruce Randazzo   +2 more
exaly